NSE filing, NSE: GODREJPROP. Summary written from the filing by ALFA Finder's alert engine.
Godrej Properties Ltd: key numbers
- Share price
- ₹1,568.00
- Market cap
- ₹47,232 Cr
- Revenue (annual)
- ₹5,131 Cr
- Net profit (annual)
- ₹1,850 Cr
- P/E (TTM)
- 35.0×Sector 34.5×
- Promoter holding
- 51.66%+0.00% QoQ
- FII holding
- 24.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Godrej Properties Ltd
All →Godrej Properties Business Update
Godrej Properties launched a Pune homebuyer research study at its Shubh Aarambh event. The company unveiled a 1,400 sq m resort-themed clubhouse at Godrej Hill Retreat.
Godrej Properties Earnings Call Transcript: Key Takeaways
Management is banking on a massive second-half launch pipeline to mask Q2 de-growth in bookings. While collections are strong, earnings quality is currently distorted by project exit accounting and back-ended delivery schedules.
- Call
- Guides 20% growth
Godrej Properties Other Announcement
Godrej Properties filed ICRA's monitoring agency report on QIP proceeds for the quarter ended September 30, 2026. The report found no material deviation from the issue objects.
Godrej Properties Investor Presentation: Key Takeaways
Godrej Properties reported Q2 FY27 booking value of INR 8,008 crore and collections of INR 5,318 crore (up 31% YoY). Strategy focuses on scalability and delivering 20% ROE by FY28.
- Call
- Guides 20% growth
Godrej Properties Results Update
Godrej Properties reported Q2 FY27 net profit of ₹154 crore and bookings of ₹8,008 crore. Operating cash flow rose 33% YoY to ₹1,584 crore.
Godrej Properties Q2 FY27 Results: Net Profit ₹145.5 Cr, Down 63.9% YoY
Godrej Properties Ltd reported revenue from operations of ₹1,935 Cr (+161.4% YoY) and net profit of ₹145.5 Cr (-63.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹145.5 Cr · -63.9% YoY
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr